Meridia: “Another Flawed Diet Pill” Or Successful Weight Loss Drug?
bbryant September 3rd, 2010
The executive editor of The New England Journal of Medicine has taken a strong position by calling Abbott Laboratories weight loss drug Meridia “another flawed diet pill.” The pill has come under significant scrutiny and will be reviewed by an FDA panel on
September 15th.
According to a company-sponsored study people who take Meridia have a slightly higher risk of a nonfatal heart attack or stroke. However, this increased risk has only been seen in patients that have some form of heart disease. Therefore, the company is intent on keeping the drug on the market but restricting it to patients that do not have any known heart problems.
The strategy was not accepted in Europe and the diet pill has been banned there. If the editors at The New England Journal of Medicine have their way, it will also be banned in the US. They contend that the risk far outweighs any benefit. Furthermore, they question if there is any real benefit at all by noting that in most instances the weight loss evidenced by patients on the drug, is generally no more than 9 pounds, or less than 5% of the body weight.
Why would a company accept such a risk by keeping the drug on the market? We don’t purport to know that, however we do know that in the pharmaceutical industry, obesity is known as the “trillion dollar disease” and that is the estimated amount of profit that could be made by a manufacturer that is able to produce a drug that is both safe and effective in treating obesity.
So far, no company has successfully done so. Currently the only other FDA approved drug for long term treatment of obesity is Xenical. However, there are two other drugs currently awaiting FDA approval. They are Contrave from Orexigen Therapeutics Inc and Lorcaserin from Arena Pharmaceuticals.
Considering the financial potential for a successful obesity drug, it is no surprise that Abbott, a big pharma company, is fighting for the right to keep Meridia on the market. As defective drug attorneys it is also no surprise to us that a big pharma company is willing to accept a very significant level of risk when the financial potential is so strong.
References:
http://www.nejm.org/doi/full/10.1056/NEJMoa1003114
http://www.realdietmeds.com/blog/
http://www.webmd.com/diet/news/20100901/weight-loss-pill-meridia-ups-heart-attack-stroke
Popularity: 1% [?]

